SEQENS is involved in the development and production of pharmaceutical solutions, personal care ingredients, and custom specialty chemical products.

SEQENS

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

SSL by Default

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Maps

WordPress

Business Management

Akshay Purohit

Human Resources

Alexandra Nowak

Production Director

Chris Benson

Group R&D Director

Christophe EYCHENNE-BARON

Engineering

Diana Gonzalez

Group Technical Director

Dominique AUDOUX

Supply Chain Director

Elie Saikali

IT Business Partner & Sustainability Director at SEQENS

Emily C.

Controller

Gail Perkins

Associate Director of Quality Assurance Systems

Glen Lindeke

Bob Huang

Managing Director

Pierre Luzeau

Europe Acquired Companies With More Than 10 Employees (Top 10K)

Europe Acquired Companies With More Than $1M in Revenue (Top 10K)

European Union (EU) Companies With More Than 100 Employees (Top 10K)

Pharmaceutical Companies (Top 10K)

Seqens is a integrated in pharmaceutical synthesis and specialty ingredients, delivering unrivalled market responsiveness and tailor-made solutions to our customers.

Private Equity Round - Seqens

Eurazeo

Seed Round - Seqens

Écully

Rhone-Alpes

France

Europe

Seqens

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens

Biophytis and SEQENS sign a partnership to produce Sarconeos (BIO101) active compound

SK Capital Partners Acquires Majority Shareholding of SEQENS, a Leader in Pharmaceuticals and Specialty Ingredients.

SK Capital Partners Acquires Majority Shareholding of SEQENS, a Leader in Pharmaceuticals and Specialty Ingredients

PCAS: Change of shareholders at Seqens - Appointment of a new Chief Executive Officer

Seqens Appoints Bob Huang Managing Director of North American CDMO Operations

Eurazeo to sell Seqens stake to SK Capital et al.

Seqens majority owner looking to sell API maker amid record-high run in healthcare valuations: report

REFILE-French pharma ingredients maker Seqens prepped for sale - sources

China

Asia

India

Finland

Philippines

HTML5

Symantec Email Security.Cloud

Wordpress

Google Analytics

Google Fonts

Apache Server

Vimeo

Office 365

jQuery

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 27, 2024 4:36 PM	2553e5b1
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 27, 2024 4:36 PM	478aef23
crunchbase trigger	general	Nov 12, 2024 12:52 PM	b528822f
crunchbase profile	general	Nov 12, 2024 8:49 PM	ec2197c2
li profile	general
translate crunchbase fundingrounds	general	Nov 12, 2024 9:22 PM	cab85cba
peers	general	Sep 27, 2024 4:36 PM	4b106ff0
news basic	general	Sep 27, 2024 4:36 PM	27b7b74a
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:SEQENS

SEQENS